Orbimed Advisors LLC
In its 13F for Q2 2026 (holdings as of June 30, 2026, filed August 14, 2026), Orbimed Advisors LLC reported 117 stock positions worth $5.3 billion. Its top holding was Edgewise Therapeutics (EWTX) at 12.0% of the portfolio, followed by Enliven Therapeutics (ELVN, 6.5%) and Eli Lilly (LLY, 5.9%). Compared with Q1 2026, it opened 31 new positions, sold out of 19, added to 33 and reduced 26. The biggest buy was a new position in Unitedhealth (UNH) and the biggest sale Boston Scientific (BSX, shares −38%).
- Most Recent 13F
- Q2 2026
- Location
- New York, NY
- CIK
- 0001055951
- Portfolio Value
- $5.3B (Q2 2026)
- SEC Filing
- 0001172661-26-003740 ↗ filed Aug 14, 2026
Holdings Value
Holdings 117 stocks · $5.3B
| EWTX Edgewise Therapeutics Inc. | 11.97% | 15,518,492 | $630.5M | No change |
| ELVN Enliven Therapeutics Inc. | 6.53% | 6,776,632 | $343.9M | Reduce -14.9% |
| LLY Eli Lilly & Co. | 5.87% | 257,900 | $309.3M | Add +8.9% |
| MBX MBX Biosciences Inc. | 3.59% | 3,428,736 | $189.3M | Reduce -5.8% |
| SVA Sinovac Biotech Ltd. | 3.50% | 2,718,735 | $184.5M | No change |
| AZN Astrazeneca PLC | 3.25% | 915,700 | $171.1M | Add +36.6% |
| GPCR Structure Therapeutics Inc. | 2.25% | 2,209,400 | $118.6M | Add +49.8% |
| SION Sionna Therapeutics Inc. | 2.13% | 2,555,877 | $112.4M | Reduce -27.6% |
| CRVS Corvus Pharmaceuticals Inc. | 2.03% | 7,165,006 | $107.0M | No change |
| AVBP Arrivent Biopharma Inc. | 2.00% | 3,027,328 | $105.2M | No change |
| GH Guardant Health Inc. | 1.66% | 583,700 | $87.6M | Add +34.1% |
| ARGX Argenx SE - ADR | 1.64% | 92,880 | $86.2M | Reduce -32.1% |
| MRK Merck & Co. Inc. | 1.62% | 663,400 | $85.2M | No change |
| QURE Uniqure NV | 1.58% | 1,807,486 | $83.3M | Reduce -15.4% |
| PRAX Praxis Precision Medicines I | 1.46% | 230,100 | $77.0M | Add +33.4% |
| EW Edwards Lifesciences Corp. | 1.43% | 834,900 | $75.5M | Reduce -32.2% |
| PRLD Prelude Therapeutics Inc. | 1.39% | 13,724,571 | $73.2M | Add +25.8% |
| ABVX Abivax SA-ADR | 1.38% | 546,522 | $72.8M | Add +17.4% |
| DYN Dyne Therapeutics Inc. | 1.36% | 3,235,684 | $71.9M | Add +10.9% |
| NTRA Natera Inc. | 1.35% | 262,000 | $71.1M | No change |
| CGON CG Oncology Inc. | 1.31% | 972,800 | $69.1M | Add +2.6% |
| UNH Unitedhealth Group Inc. | 1.27% | 161,100 | $67.0M | New |
| SPRY Ars Pharmaceuticals Inc. | 1.26% | 8,288,510 | $66.4M | No change |
| ASND Ascendis Pharma A/S | 1.24% | 244,456 | $65.2M | Add +34.3% |
| HUM Humana Inc. | 1.24% | 164,100 | $65.2M | New |
| COGT Cogent Biosciences Inc. | 1.24% | 1,681,300 | $65.1M | Add +422.0% |
| BSX Boston Scientific Corp. | 1.20% | 1,483,200 | $63.3M | Reduce -37.7% |
| ISRG Intuitive Surgical Inc. | 1.19% | 157,900 | $62.8M | Reduce -24.3% |
| MLYS Mineralys Therapeutics Inc. | 1.08% | 2,110,300 | $56.9M | Add +2.8% |
| ODTX Odyssey Therapeutics Inc. | 1.07% | 3,001,198 | $56.2M | New |
| XENE Xenon Pharmaceuticals Inc. | 1.02% | 892,471 | $53.9M | Reduce -15.8% |
| ARQT Arcutis Biotherapeutics Inc. | 1.02% | 2,042,000 | $53.5M | New |
| BMY Bristol-Myers Squibb Co. | 1.01% | 925,000 | $53.3M | No change |
| QTTB Q32 Bio Inc. | 1.00% | 4,127,987 | $52.6M | Add +83.2% |
| SYK Stryker Corp. | 0.95% | 159,100 | $50.1M | Reduce -12.8% |
| CAI Caris Life Sciences Inc. | 0.95% | 2,806,811 | $50.0M | No change |
| TMO Thermo Fisher Scientific Inc. | 0.86% | 90,700 | $45.5M | Add +95.0% |
| PVLA Palvella Therapeutics Inc. | 0.85% | 292,360 | $44.7M | Add +117.2% |
| ELV Elevance Health Inc. | 0.84% | 114,700 | $44.4M | No change |
| STTK Shattuck Labs Inc. | 0.83% | 6,306,127 | $43.8M | No change |
| UPB Upstream Bio Inc. | 0.75% | 5,693,589 | $39.4M | No change |
| CRNX Crinetics Pharmaceuticals Inc. | 0.71% | 999,000 | $37.4M | No change |
| RYTM Rhythm Pharmaceuticals Inc. | 0.68% | 322,900 | $35.9M | Add +2.8% |
| SNDX Syndax Pharmaceuticals Inc. | 0.64% | 1,542,000 | $33.7M | Add +60.2% |
| FBRX Forte Biosciences Inc. | 0.64% | 1,577,705 | $33.5M | Add +31.8% |
| CMPX Compass Therapeutics Inc. | 0.63% | 15,219,994 | $33.3M | No change |
| NKTR Nektar Therapeutics | 0.62% | 465,346 | $32.5M | Add +69.2% |
| KRYS Krystal Biotech Inc. | 0.59% | 83,200 | $30.9M | Add +20.4% |
| 0 | 0.57% | 5,680,186 | $30.3M | Reduce -8.5% |
| AXSM Axsome Therapeutics Inc. | 0.55% | 117,578 | $28.8M | Reduce -45.0% |
| KNSA Kiniksa Pharmaceuticals Inte | 0.51% | 420,600 | $26.9M | Add +132.9% |
| TRVI Trevi Therapeutics Inc. | 0.51% | 1,430,293 | $26.7M | Reduce -41.7% |
| IRON Disc Medicine Inc. | 0.50% | 357,535 | $26.2M | Reduce -66.5% |
| WST West Pharmaceutical Services | 0.48% | 70,600 | $25.3M | New |
| RLMD Relmada Therapeutics Inc. | 0.48% | 3,631,195 | $25.1M | Reduce -23.0% |
| URGN Urogen Pharma Ltd. | 0.47% | 676,187 | $24.9M | Reduce -22.8% |
| STRO Sutro Biopharma Inc. | 0.47% | 743,944 | $24.7M | Reduce -7.1% |
| SVRA Savara Inc. | 0.46% | 3,959,900 | $24.4M | Add +523.6% |
| NPCE Neuropace Inc. | 0.45% | 1,505,125 | $23.9M | Reduce -28.2% |
| AURA Aura Biosciences Inc. | 0.45% | 3,333,333 | $23.7M | New |
| ORIC Oric Pharmaceuticals Inc. | 0.41% | 2,015,000 | $21.8M | Reduce -25.2% |
| HELP Cybin Inc. | 0.41% | 3,271,400 | $21.6M | Reduce -14.7% |
| BCRX Biocryst Pharmaceuticals Inc. | 0.35% | 1,852,000 | $18.5M | Add +29.9% |
| BIOA Bioage Labs Inc. | 0.35% | 752,153 | $18.4M | Add +5.7% |
| LXEO Lexeo Therapeutics Inc. | 0.35% | 3,947,850 | $18.4M | Add +9.6% |
| WHWK Whitehawk Therapeutics Inc. | 0.34% | 3,934,296 | $18.0M | Reduce -5.6% |
| DFTX Definium Therapeutics Inc. | 0.33% | 365,400 | $17.2M | Reduce -54.5% |
| SYRE Spyre Therapeutics Inc. | 0.31% | 186,145 | $16.5M | New |
| CRBP Corbus Pharmaceuticals Holdi | 0.31% | 1,737,287 | $16.3M | No change |
| VERA Vera Therapeutics Inc. | 0.30% | 369,596 | $15.9M | No change |
| ALMS Alumis Inc. | 0.29% | 548,163 | $15.4M | No change |
| EYPT Eyepoint Inc. | 0.29% | 1,069,147 | $15.3M | No change |
| WAT Waters Corp. | 0.29% | 40,300 | $15.1M | New |
| MNPR Monopar Therapeutics Inc. | 0.28% | 157,423 | $14.6M | New |
| TVTX Travere Therapeutics Inc. | 0.27% | 253,000 | $14.4M | New |
| TSHA Taysha Gene Therapies Inc. | 0.26% | 2,000,000 | $13.6M | New |
| BIIB Biogen Inc. | 0.25% | 61,600 | $13.3M | No change |
| RVMD Revolution Medicines Inc. | 0.25% | 70,500 | $13.2M | Add +35.6% |
| DNTH Dianthus Therapeutics Inc. | 0.21% | 115,000 | $11.2M | New |
| SPRB Spruce Biosciences Inc. | 0.21% | 200,000 | $10.8M | New |
| LFST Lifestance Health Group Inc. | 0.19% | 947,400 | $10.1M | Add +89.5% |
| ERAS Erasca Inc. | 0.17% | 495,900 | $9.1M | New |
| TARA Protara Therapeutic Inc. | 0.16% | 2,220,000 | $8.5M | New |
| KROS Keros Therapeutics Inc. | 0.15% | 759,155 | $8.1M | No change |
| JANX Janux Therapeutics Inc. | 0.15% | 524,700 | $8.1M | Reduce -46.7% |
| TECX Tectonic Therapeutic Inc. | 0.15% | 226,600 | $7.8M | No change |
| ACET Adicet Bio Inc. | 0.14% | 844,787 | $7.3M | Reduce -17.8% |
| PHVS Pharvaris NV | 0.13% | 205,400 | $7.1M | No change |
| ANRO Alto Neuroscience Inc. | 0.13% | 257,852 | $6.8M | Add +53.9% |
| ZNTL Zentalis Pharmaceuticals Inc. | 0.13% | 1,390,576 | $6.7M | New |
| DRUG Bright Minds Biosciences Inc. | 0.12% | 93,000 | $6.5M | Add +132.5% |
| ALXO Alx Oncology Holdings Inc. | 0.11% | 2,866,256 | $5.9M | No change |
| XLO Xilio Therapeutics Inc. | 0.11% | 592,300 | $5.7M | New |
| BCAX Bicara Therapeutics Inc. | 0.11% | 191,100 | $5.7M | Reduce -71.4% |
| IMA Imagenebio Inc. | 0.10% | 909,269 | $5.4M | Add +140.2% |
| PTGX Protagonist Therapeutics Inc. | 0.10% | 42,100 | $5.2M | No change |
| ALNY Alnylam Pharmaceuticals Inc. | 0.10% | 17,000 | $5.1M | Reduce -85.7% |
| PALI Palisade Bio Inc. | 0.09% | 2,333,000 | $4.9M | No change |
| ATAI Ataibeckley Inc. | 0.08% | 797,500 | $4.2M | Add +129.8% |
| PTCT PTC Therapeutics Inc. | 0.08% | 49,100 | $4.0M | No change |
| AORT Artivion Inc. | 0.07% | 175,000 | $3.9M | Add +15.9% |
| NMRA Neumora Therapeutics Inc. | 0.07% | 2,139,882 | $3.6M | New |
| ACAD Acadia Pharmaceuticals Inc. | 0.07% | 137,000 | $3.5M | New |
| AMLX Amylyx Pharmaceuticals Inc. | 0.06% | 183,400 | $3.3M | New |
| TYRA Tyra Biosciences Inc. | 0.06% | 102,000 | $3.3M | New |
| RAPP Rapport Therapeutics Inc. | 0.06% | 76,616 | $3.2M | New |
| AGMB Agomab Therapeutics NV | 0.05% | 192,740 | $2.5M | New |
| TARS Tarsus Pharmaceuticals Inc. | 0.04% | 35,581 | $2.2M | New |
| ACRS Aclaris Therapeutics Inc. | 0.04% | 421,500 | $2.2M | New |
| CYTK Cytokinetics Inc. | 0.04% | 25,800 | $2.2M | New |
| NSPR Inspiremd Inc. | 0.04% | 3,133,405 | $2.2M | No change |
| OCUL Ocular Therapeutix Inc. | 0.04% | 220,000 | $2.2M | New |
| EVMN Evommune Inc. | 0.04% | 161,000 | $2.1M | New |
| BLTE Belite Bio Inc. - ADR | 0.04% | 13,300 | $2.0M | New |
| OVID Ovid Therapeutics Inc. | 0.04% | 747,000 | $2.0M | New |
| EPRX Eupraxia Pharmaceuticals Inc. | 0.03% | 269,000 | $1.8M | New |
| TRAW Traws Pharma Inc. | 0.02% | 1,203,260 | $1.0M | Add +98.7% |
Options reported separately and not counted above: XBI puts ($47.5M), ABVX calls ($26.7M), PTGX calls ($18.4M), RVMD calls ($9.4M), PVLA calls ($6.1M), UNH calls ($4.2M), ELV calls ($3.9M), SLS puts ($1.4M).
Other holdings (4): bonds, preferreds, convertibles and warrants · $12.6M (not counted above)
| Security | Class | Shares / Principal | Value | Change |
|---|---|---|---|---|
| TRAVERE THERAPEUTICS INC (TVTX 0.5 05/15/32) | NOTE 0.500% 5/1 · principal | 5,000,000 | $5.9M | New |
| REVOLUTION MEDICINES INC (RVMD 0.5 05/01/33) | NOTE 0.500% 5/0 · principal | 3,500,000 | $4.4M | New |
| COGENT BIOSCIENCES INC (COGT 1.625 11/15/31) | NOTE 1.625%11/1 · principal | 1,000,000 | $1.2M | No change |
| VIRIDIAN THERAPEUTICS INC | NOTE 1.750% 5/1 · principal | 1,000,000 | $1.1M | New |
Total filed on the 13F, all lines: $5.3B.
Portfolio Sells Q1 2026 → Q2 2026
| BSX Boston Scientific Corp. | Reduce -37.7% | 1.20% | −2.18 |
| PFE Pfizer Inc. | Sold out | 0.00% | −1.24 |
| DHR Danaher Corp. | Sold out | 0.00% | −1.14 |
| SION Sionna Therapeutics Inc. | Reduce -27.6% | 2.13% | −1.07 |
| IRON Disc Medicine Inc. | Reduce -66.5% | 0.50% | −1.05 |
| ISRG Intuitive Surgical Inc. | Reduce -24.3% | 1.19% | −0.98 |
| EW Edwards Lifesciences Corp. | Reduce -32.2% | 1.43% | −0.80 |
| ALNY Alnylam Pharmaceuticals Inc. | Reduce -85.7% | 0.10% | −0.79 |
| ESPR Esperion Therapeutics Inc. | Sold out | 0.00% | −0.66 |
| ARGX Argenx SE - ADR | Reduce -32.1% | 1.64% | −0.63 |
| ELVN Enliven Therapeutics Inc. | Reduce -14.9% | 6.53% | −0.53 |
| BTSG Brightspring Health Services | Sold out | 0.00% | −0.48 |
| SYK Stryker Corp. | Reduce -12.8% | 0.95% | −0.41 |
| XENE Xenon Pharmaceuticals Inc. | Reduce -15.8% | 1.02% | −0.37 |
| ORIC Oric Pharmaceuticals Inc. | Reduce -25.2% | 0.41% | −0.36 |
| AMGN Amgen Inc. | Sold out | 0.00% | −0.32 |
| ALHC Alignment Healthcare Inc. | Sold out | 0.00% | −0.32 |
| AXSM Axsome Therapeutics Inc. | Reduce -45.0% | 0.55% | −0.27 |
| RLMD Relmada Therapeutics Inc. | Reduce -23.0% | 0.48% | −0.27 |
| REGN Regeneron Pharmaceuticals | Sold out | 0.00% | −0.26 |
| CARL Carlsmed Inc. | Sold out | 0.00% | −0.26 |
| BCAX Bicara Therapeutics Inc. | Reduce -71.4% | 0.11% | −0.19 |
| GILD Gilead Sciences Inc. | Sold out | 0.00% | −0.19 |
| HRTX Heron Therapeutics Inc. | Sold out | 0.00% | −0.18 |
| NPCE Neuropace Inc. | Reduce -28.2% | 0.45% | −0.17 |
| AVTX Avalo Therapeutics Inc. | Sold out | 0.00% | −0.16 |
| JANX Janux Therapeutics Inc. | Reduce -46.7% | 0.15% | −0.16 |
| TRVI Trevi Therapeutics Inc. | Reduce -41.7% | 0.51% | −0.16 |
| CMPS Compass Pathways PLC | Sold out | 0.00% | −0.14 |
| ADCT Adc Therapeutics SA | Sold out | 0.00% | −0.11 |
| CGEM Cullinan Therapeutics Inc. | Sold out | 0.00% | −0.08 |
| JBIO Jade Biosciences Inc. | Sold out | 0.00% | −0.06 |
| CCCC C4 Therapeutics Inc. | Sold out | 0.00% | −0.05 |
| RCEL Avita Medical Inc. | Sold out | 0.00% | −0.05 |
| KALV Kalvista Pharmaceuticals Inc. | Sold out | 0.00% | −0.04 |
| VTGN Vistagen Therapeutics Inc. | Sold out | 0.00% | −0.04 |
| ACET Adicet Bio Inc. | Reduce -17.8% | 0.14% | −0.02 |
| DFTX Definium Therapeutics Inc. | Reduce -54.5% | 0.33% | −0.02 |
| HELP Cybin Inc. | Reduce -14.7% | 0.41% | −0.01 |
| WHWK Whitehawk Therapeutics Inc. | Reduce -5.6% | 0.34% | +0.02 |
| STRO Sutro Biopharma Inc. | Reduce -7.1% | 0.47% | +0.02 |
| 0 | Reduce -8.5% | 0.57% | +0.08 |
| URGN Urogen Pharma Ltd. | Reduce -22.8% | 0.47% | +0.12 |
| QURE Uniqure NV | Reduce -15.4% | 1.58% | +0.79 |
| MBX MBX Biosciences Inc. | Reduce -5.8% | 3.59% | +1.14 |
Portfolio Buys Q1 2026 → Q2 2026
| UNH Unitedhealth Group Inc. | New | 1.27% | +1.27 |
| HUM Humana Inc. | New | 1.24% | +1.24 |
| ODTX Odyssey Therapeutics Inc. | New | 1.07% | +1.07 |
| ARQT Arcutis Biotherapeutics Inc. | New | 1.02% | +1.02 |
| COGT Cogent Biosciences Inc. | Add +422.0% | 1.24% | +0.95 |
| LLY Eli Lilly & Co. | Add +8.9% | 5.87% | +0.95 |
| GH Guardant Health Inc. | Add +34.1% | 1.66% | +0.75 |
| QTTB Q32 Bio Inc. | Add +83.2% | 1.00% | +0.67 |
| GPCR Structure Therapeutics Inc. | Add +49.8% | 2.25% | +0.64 |
| PRLD Prelude Therapeutics Inc. | Add +25.8% | 1.39% | +0.55 |
| WST West Pharmaceutical Services | New | 0.48% | +0.48 |
| PVLA Palvella Therapeutics Inc. | Add +117.2% | 0.85% | +0.47 |
| AURA Aura Biosciences Inc. | New | 0.45% | +0.45 |
| SVRA Savara Inc. | Add +523.6% | 0.46% | +0.38 |
| TMO Thermo Fisher Scientific Inc. | Add +95.0% | 0.86% | +0.35 |
| KNSA Kiniksa Pharmaceuticals Inte | Add +132.9% | 0.51% | +0.31 |
| SYRE Spyre Therapeutics Inc. | New | 0.31% | +0.31 |
| ASND Ascendis Pharma A/S | Add +34.3% | 1.24% | +0.30 |
| WAT Waters Corp. | New | 0.29% | +0.29 |
| MNPR Monopar Therapeutics Inc. | New | 0.28% | +0.28 |
| TVTX Travere Therapeutics Inc. | New | 0.27% | +0.27 |
| TSHA Taysha Gene Therapies Inc. | New | 0.26% | +0.26 |
| AZN Astrazeneca PLC | Add +36.6% | 3.25% | +0.26 |
| DNTH Dianthus Therapeutics Inc. | New | 0.21% | +0.21 |
| ABVX Abivax SA-ADR | Add +17.4% | 1.38% | +0.21 |
| PRAX Praxis Precision Medicines I | Add +33.4% | 1.46% | +0.21 |
| SPRB Spruce Biosciences Inc. | New | 0.21% | +0.21 |
| KRYS Krystal Biotech Inc. | Add +20.4% | 0.59% | +0.18 |
| ERAS Erasca Inc. | New | 0.17% | +0.17 |
| NKTR Nektar Therapeutics | Add +69.2% | 0.62% | +0.17 |
| DYN Dyne Therapeutics Inc. | Add +10.9% | 1.36% | +0.17 |
| TARA Protara Therapeutic Inc. | New | 0.16% | +0.16 |
| RVMD Revolution Medicines Inc. | Add +35.6% | 0.25% | +0.14 |
| SNDX Syndax Pharmaceuticals Inc. | Add +60.2% | 0.64% | +0.13 |
| ZNTL Zentalis Pharmaceuticals Inc. | New | 0.13% | +0.13 |
| LFST Lifestance Health Group Inc. | Add +89.5% | 0.19% | +0.12 |
| XLO Xilio Therapeutics Inc. | New | 0.11% | +0.11 |
| NMRA Neumora Therapeutics Inc. | New | 0.07% | +0.07 |
| BIOA Bioage Labs Inc. | Add +5.7% | 0.35% | +0.07 |
| ACAD Acadia Pharmaceuticals Inc. | New | 0.07% | +0.07 |
| RYTM Rhythm Pharmaceuticals Inc. | Add +2.8% | 0.68% | +0.06 |
| AMLX Amylyx Pharmaceuticals Inc. | New | 0.06% | +0.06 |
| TYRA Tyra Biosciences Inc. | New | 0.06% | +0.06 |
| RAPP Rapport Therapeutics Inc. | New | 0.06% | +0.06 |
| IMA Imagenebio Inc. | Add +140.2% | 0.10% | +0.06 |
| DRUG Bright Minds Biosciences Inc. | Add +132.5% | 0.12% | +0.06 |
| ATAI Ataibeckley Inc. | Add +129.8% | 0.08% | +0.05 |
| AGMB Agomab Therapeutics NV | New | 0.05% | +0.05 |
| BCRX Biocryst Pharmaceuticals Inc. | Add +29.9% | 0.35% | +0.04 |
| ANRO Alto Neuroscience Inc. | Add +53.9% | 0.13% | +0.04 |
Options Activity Q1 2026 → Q2 2026
| MDXH Mdxhealth | call | Sold out | 124,306,000 | $285.9Mbefore exit |
| RCEL Avita Medical Inc. | call | Sold out | 40,966,100 | $154.4Mbefore exit |
| XBI SS SPDR S&P Biotech ETF | put | New | 300,000 | $47.5M |
| ABVX Abivax SA-ADR | call | New | 200,000 | $26.7M |
| PTGX Protagonist Therapeutics Inc. | call | New | 150,000 | $18.4M |
| QGEN Qiagen N.V. | call | Sold out | 250,000 | $10.0Mbefore exit |
| RVMD Revolution Medicines Inc. | call | New | 50,000 | $9.4M |
| PVLA Palvella Therapeutics Inc. | call | Reduce -20.0% | 40,000 | $6.1M |
| UNH Unitedhealth Group Inc. | call | New | 10,000 | $4.2M |
| ELV Elevance Health Inc. | call | New | 10,000 | $3.9M |
| SLNO Soleno Therapeutics Inc. | call | Sold out | 100,000 | $3.3Mbefore exit |
| SLS Sellas Life Sciences Group I | put | New | 92,500 | $1.4M |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
Notes & Other Activity Q1 2026 → Q2 2026
| MYGN Myriad Genetics Inc. | COM · principal | Sold out | 125,000,000 | $122.9Mbefore exit |
| RCEL Avita Medical Inc. | COM · principal | Sold out | 40,500,000 | $40.5Mbefore exit |
| TRAVERE THERAPEUTICS INC (TVTX 0.5 05/15/32) | NOTE 0.500% 5/1 · principal | New | 5,000,000 | $5.9M |
| REVOLUTION MEDICINES INC (RVMD 0.5 05/01/33) | NOTE 0.500% 5/0 · principal | New | 3,500,000 | $4.4M |
| VIRIDIAN THERAPEUTICS INC | NOTE 1.750% 5/1 · principal | New | 1,000,000 | $1.1M |
Bonds, preferreds, convertibles and warrants; not part of the stock holdings or percentages above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 117 | $5.3B | EWTX, ELVN, LLY, MBX, SVA |
| Q1 2026 | 105 | $4.4B | EWTX, ELVN, LLY, SVA, BSX |
| Q4 2025 | 104 | $4.9B | EWTX, LLY, BSX, SVA, EW |
| Q3 2025 | 98 | $4.2B | EWTX, BSX, LLY, SVA, ELVN |
| Q2 2025 | 97 | $4.0B | SVA, BSX, LLY, EWTX, ELVN |
| Q1 2025 | 106 | $4.2B | SVA, EWTX, BSX, LLY, ELVN |
| Q4 2024 | 111 | $4.8B | EWTX, SVA, BSX, LLY, ISRG |
| Q3 2024 | 109 | $5.5B | EWTX, SVA, LLY, BSX, ISRG |
| Q2 2024 | 108 | $5.0B | SVA, LLY, EWTX, BSX, ISRG |
| Q1 2024 | 112 | $5.4B | SVA, LLY, EWTX, BSX, ISRG |